Drug Profile
Research programme: botulinum toxins - Ipsen Bioinnovation
Alternative Names: botulinum neurotoxins; SXNLatest Information Update: 11 Nov 2020
Price :
$50
*
At a glance
- Originator Syntaxin
- Developer Ipsen Bioinnovation
- Class Bacterial proteins; Bacterial toxins; Botulinum toxins; Recombinant proteins
- Mechanism of Action Acetylcholine inhibitors; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 05 Nov 2020 Ipsen collaborates with Synthace to advance development of targeted secretion inhibitors
- 28 Dec 2018 No recent reports of development identified for research development in Unspecified in United Kingdom
- 15 Dec 2016 Preclinical development is ongoing United Kingdom (Ipsen pipeline, December 2016)